Goldman Sachs Maintains Neutral on Calumet, Raises Price Target to $45

Benzinga Newsdesk www.benzinga.com Positive 53.0%

Neg 0% Neu 0% Pos 53%

Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $40 to $45.